Novelgenix Theraps Company Profile

What is the competitive landscape for NOVELGENIX THERAPS

NOVELGENIX THERAPS has one approved drug.

Summary for Novelgenix Theraps

US Patents:	0
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Novelgenix Theraps

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novelgenix Theraps	NAPROXEN SODIUM	naproxen sodium	TABLET;ORAL	207612-001	Nov 16, 2018		DISCN	No	No

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Novel Labs Inc
• Novelgenix Theraps
• Noven
• Noven Pharms Inc
• Noven Therap

Last updated: June 23, 2026

Pharmaceutical Competitive Landscape Analysis of Novelgenix Theraps: Market Position, Strengths, and Strategic Patent/Risk Priorities

No sufficient, citable, drug-specific facts (active ingredient, FDA approval status, Orange Book listings, patent numbers/expiration dates, and/or litigation records) are available to produce a complete and accurate competitive landscape for “Novelgenix Theraps.”

Key Takeaways

• No actionable patent-protected landscape, exclusivity timeline, or generic/biosimilar entry risk can be stated without drug-identifying regulatory and patent records.
• No market-position assessment can be quantified without validated prescribing, sales, or formulary adoption data tied to an identifiable product/NDC and active moiety.
• No licensing or litigation strategy can be mapped without verified, case-specific court filings, settlement terms, and listed patents.

FAQs

1. What patents protect Novelgenix Theraps in the US Orange Book?
2. When does Novelgenix Theraps lose exclusivity under 5-year/3-year exclusivity and patent expiration schedules?
3. What Paragraph IV challenges could threaten Novelgenix Theraps exclusivity, and which generic filers are involved?
4. What formulations or method-of-use claims could block generic entry for Novelgenix Theraps?
5. What FDA approval pathway and exclusivity category applies to Novelgenix Theraps, and what biosimilar or generic risk follows?

References

No sources provided.